Lantheus Holdings, Inc.

Valuation Analysis

About the Company

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in diagnosis and treatment of heart, cancer, and other diseases worldwide. The company offers DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with pros

Lantheus Holdings, Inc. Stock at a Glance

Lantheus Holdings, Inc. (LNTH) is currently trading at $104.52 with a market capitalization of $6.8B. The trailing P/E ratio stands at 24.95x, with a forward P/E of 16.34x. The 52-week range spans from $47.25 to $104.57; the current price is 0% below the yearly high. Year-over-year revenue growth stands at +1.2%. The net profit margin stands at 18.05%.

💰 Dividend

Lantheus Holdings, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

13 analysts rate Lantheus Holdings, Inc. (LNTH) on consensus: Strong Buy. The average price target is $105.23, implying +0.68% from the current price. Analyst price targets range from $76.00 to $117.00.

Lantheus Holdings, Inc.: The Investment Case in Detail

Lantheus Holdings, Inc. (LNTH) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Earnings growth of 76.5% is outpacing revenue, a sign of operational leverage — fixed costs are being absorbed across a larger base. With a gross margin near 60.48%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 18.05%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

The Bear Case

Revenue growth has slowed to just 1.2%, which is below nominal GDP — the business is no longer outgrowing the broader economy. Short interest sits at 11.2% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

What to Watch Next

• The forward P/E of 16.34x is meaningfully below the trailing 24.95x — analysts expect earnings to step up; the next earnings release is the test.
• The share is trading at 99.9% of its 52-week range — a break above the recent high opens technical upside, a failure here often invites profit-taking.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Risk Profile

The data points to elevated short interest (11.2%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Lantheus Holdings, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.